FUNDAMENTALS |
MarketCap: |
2.95 mill
|
EPS: |
-0.760
|
P/E: |
-0.0528
|
Earnings Date: |
Mar 12, 2024 |
SharesOutstanding: |
73.56 mill
|
Avg Daily Volume: |
2.24 mill
|
RATING
2024-01-26 |
S+
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.0528 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-0.01x
|
Company: PE -0.0528 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0271 - 0.0531
( +/- 32.42%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-04-10 | Petrini Maria Carolina | Buy | 400 000 | Nonqualified Stock Option (Right to Buy) |
2023-04-10 | Petrini Maria Carolina | Buy | 0 | |
2023-02-01 | Mcintyre Gail Frances | Buy | 700 000 | Stock Option (Right to Buy) |
2023-02-01 | Geller Robert B. | Buy | 400 000 | Stock Option (Right to Buy) |
2023-02-01 | Howard Rudy | Buy | 400 000 | Stock Option (Right to Buy) |
INSIDER POWER |
100.00
|
Last
91 transactions |
Buy:
72 486 477 | Sell:
119 333 |
Forecast:
01:40 - $0.0780
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0401 (-13.39% )
|
Volume |
4.04 mill
|
Avg. Vol. |
2.24 mill
|
% of Avg. Vol |
180.15 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For ARAV
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.